Boehringer Ingelheim India today shared its roadmap of partnerships and patient access programmes to sustain its growth momentum in 2021. The Company, one of the fastest growing amongst the top 10 multinational pharmaceutical companies in India, is market leader in the patented non-insulin market.
Boehringer Ingelheim had announced the appointment of Vani Manja as the Managing Director for India, effective January 1, 2021. In this role, she manages the Company’s operations in India and neighbouring markets.
Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”
Free Membership Required
You must be a Free member to access this content.
